Kalohexis Appoints Xuan Hui, B.Med., M.S., Ph.D., as Director of Corporate Strategy
NORTHBROOK, Ill., June 18, 2026 /PRNewswire/ -- Kalohexis, Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced the appointment of Xuan Hui, B.Med., M.S.,...
NORTHBROOK, Ill., June 18, 2026 /PRNewswire/ -- Kalohexis, Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced the appointment of Xuan Hui, B.Med., M.S.,...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.